Show simple item record

dc.contributor.authorStraus, DJ
dc.contributor.authorDlugosz-Danecka, M
dc.contributor.authorAlekseev, S
dc.contributor.authorIlles, A
dc.contributor.authorPicardi, M
dc.contributor.authorLech-Maranda, E
dc.contributor.authorFeldman, T
dc.contributor.authorSavage, KJ
dc.contributor.authorSmolewski, P
dc.contributor.authorBartlett, NL
dc.contributor.authorGallamini, A
dc.contributor.authorWalewski, JA
dc.contributor.authorRamchandren, R
dc.contributor.authorZinzani, PL
dc.contributor.authorConnors, JM
dc.contributor.authorJolin, H
dc.contributor.authorLiu, R
dc.contributor.authorFenton, K
dc.contributor.authorFanale, M
dc.contributor.authorRadford, John A
dc.date.accessioned2019-11-19T16:01:08Z
dc.date.available2019-11-19T16:01:08Z
dc.date.issued2019en
dc.identifier.citationStraus D, Dlugosz-Danecka M, Alekseev S, Illes A, Picardi M, Lech-Maranda E, et al. Brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: three-year update of the ECHELON-1 study. J Clin Oncol. 2019;37(15).en
dc.identifier.doi10.1200/JCO.2019.37.15_suppl.7532en
dc.identifier.urihttp://hdl.handle.net/10541/622468
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2019.37.15_suppl.7532en
dc.titleBrentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: three-year update of the ECHELON-1 studyen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMemorial Sloan Kettering Cancer Center, New York, NYen
dc.identifier.journalJournal of Clinical Oncologyen


This item appears in the following Collection(s)

Show simple item record